Relay Therapeutics (RLAY) Operating Margin (2021 - 2026)
Relay Therapeutics (RLAY) reported Operating Margin of 2619.67% for Q1 2026, down 151446.0% year-over-year from N/an in Q1 2025, and down 202.45% on a QoQ basis from 866.14% in Q4 2025.
Relay Therapeutics (RLAY) has 6 years of Operating Margin data on file, last reported at 2619.67% in Q1 2026.
- Quarterly Operating Margin fell 151446.0% year-over-year to 2619.67% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2776.6% (up 200233.0% YoY) and the FY2025 annual result came in at 1971.59%, up 175048.0% from the prior year.
- Operating Margin slipped to 2619.67% in Q1 2026 per RLAY's latest filing, from 866.14% in the prior quarter.
- Across five years, Operating Margin topped out at 9219600.0% in Q4 2023 and bottomed at 89117.65% in Q2 2023.
- The 5-year median for Operating Margin is 11351.11% (2025), against an average of 690655.84%.
- Peak annual rise in Operating Margin reached 924839486 bps in 2023, while the deepest fall reached 6779956 bps in 2023.
- Tracing RLAY's Operating Margin over 5 years: stood at 28794.86% in 2022, then jumped by 32118 bps to 9219600.0% in 2023, then slumped by 100 bps to 903.0% in 2024, then grew by 4 bps to 866.14% in 2025, then tumbled by 202 bps to 2619.67% in 2026.
- Per Business Quant, the three latest RLAY Operating Margin figures stand at 2619.67% (Q1 2026), 866.14% (Q4 2025), and 11351.11% (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Relay Therapeutics | 2.53 Bn | 2.53 Bn | - | -2,619.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,619.67% |
| Dec 31, 2025 | -866.14% |
| Jun 30, 2025 | -11,351.11% |
| Mar 31, 2025 | -1,105.21% |
| Mar 31, 2024 | -903.00% |
| Dec 31, 2023 | 9,219,600.00% |
| Sep 30, 2023 | -291.95% |
| Jun 30, 2023 | -89,117.65% |
| Mar 31, 2023 | -44,768.58% |
| Dec 31, 2022 | -28,794.86% |
| Sep 30, 2022 | -24,968.60% |
| Jun 30, 2022 | -21,318.08% |
| Mar 31, 2022 | -14,969.21% |
| Dec 31, 2021 | -11,944.09% |
| Sep 30, 2021 | -9,157.66% |
| Jun 30, 2021 | -22,936.02% |
| Mar 31, 2021 | -4,454.31% |